South Korea
# |
Name |
Price to Earnings Ratio (P/E) |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
1,508.85 |
Feb. 3, 2025 | USD 15.77 | -2.26% |
|
South Korea |
|
2 |
154.16 |
Feb. 3, 2025 | USD 32.21 | -3.61% |
|
South Korea |
|
3 |
153.98 |
Feb. 3, 2025 | USD 8.58 | -5.12% |
|
South Korea |
|
4 |
128.04 |
Feb. 3, 2025 | USD 5.00 | -8.15% |
|
South Korea |
|
5 |
99.45 |
Feb. 3, 2025 | USD 34.59 | -4.65% |
|
South Korea |
|
6 |
94.59 |
Feb. 3, 2025 | USD 83.97 | -5.00% |
|
South Korea |
|
7 |
82.37 |
Feb. 3, 2025 | USD 54.68 | -7.62% |
|
South Korea |
|
8 |
79.69 |
Feb. 3, 2025 | USD 745.69 | 1.15% |
|
South Korea |
|
9 |
73.49 |
Feb. 3, 2025 | USD 77.77 | -3.69% |
|
South Korea |
|
10 |
65.48 |
Feb. 3, 2025 | USD 11.86 | -0.20% |
|
South Korea |
|
11 |
64.89 |
Feb. 3, 2025 | USD 119.86 | -2.20% |
|
South Korea |
|
12 |
60.01 |
Feb. 3, 2025 | USD 8.44 | -2.89% |
|
South Korea |
|
13 |
36.63 |
Feb. 3, 2025 | USD 33.57 | -2.13% |
|
South Korea |
|
14 |
35.96 |
Feb. 3, 2025 | USD 1.18 | -3.42% |
|
South Korea |
|
15 |
19.16 |
Feb. 3, 2025 | USD 159.35 | -4.24% |
|
South Korea |
|
16 |
19.08 |
Feb. 3, 2025 | USD 6.82 | -1.91% |
|
South Korea |
|
17 |
18.38 |
Feb. 3, 2025 | USD 1.89 | -1.74% |
|
South Korea |
|
18 |
16.05 |
Feb. 3, 2025 | USD 7.33 | -4.07% |
|
South Korea |
|
19 |
15.15 |
Feb. 3, 2025 | USD 18.22 | -3.57% |
|
South Korea |
|
20 |
15.10 |
Feb. 3, 2025 | USD 4.14 | -7.03% |
|
South Korea |
|
21 |
14.84 |
Feb. 3, 2025 | USD 3.22 | 0.07% |
|
South Korea |
|
22 |
14.40 |
Feb. 3, 2025 | USD 5.23 | -2.06% |
|
South Korea |
|
23 |
13.34 |
Feb. 3, 2025 | USD 15.49 | -2.92% |
|
South Korea |
|
24 |
13.13 |
Feb. 3, 2025 | USD 89.76 | -4.42% |
|
South Korea |
|
25 |
13.08 |
Feb. 3, 2025 | USD 9.81 | -0.42% |
|
South Korea |
|
26 |
13.07 |
Feb. 3, 2025 | USD 9.85 | -4.50% |
|
South Korea |
|
27 |
12.55 |
Feb. 3, 2025 | USD 2.87 | -2.35% |
|
South Korea |
|
28 |
12.52 |
Feb. 3, 2025 | USD 11.00 | -3.03% |
|
South Korea |
|
29 |
11.75 |
Feb. 3, 2025 | USD 9.80 | -1.72% |
|
South Korea |
|
30 |
10.27 |
Feb. 3, 2025 | USD 23.36 | -2.28% |
|
South Korea |
|
31 |
10.00 |
Feb. 3, 2025 | USD 11.62 | -0.90% |
|
South Korea |
|
32 |
9.82 |
Feb. 3, 2025 | USD 15.36 | -2.10% |
|
South Korea |
|
33 |
9.11 |
Feb. 3, 2025 | USD 65.38 | -0.04% |
|
South Korea |
|
34 |
7.48 |
Feb. 3, 2025 | USD 16.51 | 0.47% |
|
South Korea |
|
35 |
5.51 |
Feb. 3, 2025 | USD 4.07 | -1.95% |
|
South Korea |
|
36 |
5.39 |
Feb. 3, 2025 | USD 7.90 | -1.67% |
|
South Korea |
|
37 |
5.16 |
Feb. 3, 2025 | USD 3.69 | -1.06% |
|
South Korea |
|
38 |
4.99 |
Feb. 3, 2025 | USD 13.69 | -2.57% |
|
South Korea |
|
39 |
4.98 |
Feb. 3, 2025 | USD 12.66 | -2.66% |
|
South Korea |
|
40 |
4.74 |
Feb. 3, 2025 | USD 56.39 | -4.53% |
|
South Korea |
|
41 |
4.11 |
Feb. 3, 2025 | USD 31.05 | -1.12% |
|
South Korea |
|
42 |
-1.10 |
Feb. 3, 2025 | USD 0.29 | -4.87% |
|
South Korea |
|
43 |
-1.13 |
Feb. 3, 2025 | USD 0.50 | -4.09% |
|
South Korea |
|
44 |
-1.37 |
Feb. 3, 2025 | USD 1.97 | -3.64% |
|
South Korea |
|
45 |
-1.43 |
Feb. 3, 2025 | USD 1.23 | -3.88% |
|
South Korea |
|
46 |
-1.70 |
Feb. 3, 2025 | USD 1.73 | -2.46% |
|
South Korea |
|
47 |
-2.00 |
Feb. 3, 2025 | USD 1.42 | -2.25% |
|
South Korea |
|
48 |
-2.69 |
Feb. 3, 2025 | USD 8.02 | 4.65% |
|
South Korea |
|
49 |
-2.89 |
Feb. 3, 2025 | USD 3.04 | -3.81% |
|
South Korea |
|
50 |
-3.02 |
Feb. 3, 2025 | USD 2.33 | -4.21% |
|
South Korea |
The Healthcare company in South Korea with the highest Price to Earnings Ratio (P/E) is Seegene, Inc. (KOSDAQ: 096530.KQ) at 1,508.85.
The Healthcare company in South Korea with the lowest Price to Earnings Ratio (P/E) is ALTEOGEN Inc. (KOSDAQ: 196170.KQ) at -5,602.48.
The top 10 Healthcare companies in South Korea by Price to Earnings Ratio (P/E) are Seegene, Inc., SK bioscience Co.,Ltd., Samil Pharmaceutical Co.,Ltd, Pharmicell Co., Ltd., Celltrion Pharm, Inc., Yuhan Corporation, ST Pharm Co.,Ltd., Samsung Biologics Co.,Ltd., Medy-Tox Inc. and DIO Corporation.
The bottom 10 Healthcare companies in South Korea by Price to Earnings Ratio (P/E) are ALTEOGEN Inc., ABL Bio Inc., SK Biopharmaceuticals Co., Ltd., HLB Life Science Co., Ltd., Peptron, Inc., Yungjin Pharm. Co., Ltd., Anterogen.Co.,Ltd., Green Cross Corporation, Bioneer Corporation and Oscotec Inc..